Australia Daily Briefing

Australian data centre operator Firmus is fighting to close its IPO book as institutional investors balk at the premium valuation, according to Sydney Morning Herald and The Age. Lead underwriters are working to clear demand that hasn't materialized at the indicated price range. For NEXTDC (NXT.AU) — the ASX's benchmark listed data centre — the story is mixed: short-term overhang from sector re-rating, but long-term positive if the Firmus supply gap remains unaddressed. The RBA's rate trajectory is the macro variable: higher-for-longer rates compress infrastructure IPO multiples through the discount rate, a dynamic playing out in real time with Firmus.

Noxopharm (NOX) received constructive FDA feedback supporting its planned Phase II clinical trial for autoimmune drug candidate SOF-SKN — a de-risking event that the ASX small-cap biotech market typically re-rates materially. Pre-Phase II FDA clearance removes a key execution risk and opens the path to formal IND submission, typically 6-18 months ahead. With CSL and Clarity Pharmaceuticals also featuring in today's ASX healthcare news, Australian biotech is having a better day than the banks.

Newmont Mining (NEM) +1.77% is the ASX-related beneficiary of today's geopolitical risk-off flows — gold rising as global investors hedge against Hormuz disruption, Saudi airport strikes, and AI bubble warning signals simultaneously. For Australian super funds with NEM as a commodity diversifier, the gold bid is meaningful: a sustained gold price above $2,300/oz translates to significant NEM FCF expansion. Watch for Australian gold junior miners (Northern Star, Evolution Mining) to follow with a delayed ASX session reaction.